Connect your AI

United Therapeutics UTHR Tyvaso DPI — Loss related to commercial supply agreement

Similar metrics at other companies

UISGain Loss On Contract Termination

-$800K-300%

MATWGain (Loss) Related To Contractual Dispute

-$2.18M-23.8%

ADNTGain Loss On Contract Termination

$2M0.0%

AATLoss On Contract Termination For Default

$7.8M-4.9%

KLICGain Loss On Contract Termination

$0—

TMCGain Loss On Contract Termination

-$49.75K—

Other financials

Income statement

Revenue$781.5M-1.6%

Gross profit$648.1M-7.7%

Operating income$325.8M-14.9%

Net income$274.9M-14.7%

EPS (diluted)$5.82-12.2%

Balance sheet

Cash & equivalents$1.3B-32.6%

Total debt$12.2M—

Total equity$5.9B-13.3%

Total assets$6.7B-13.3%

Cash flow

Operating cash flow$463.3M+0.5%

CapEx$100.8M+34.6%

Free cash flow$362.5M-6.2%

Valuation

Market cap$23B+84.1%

P/E17.9×+7.8×

P/S7.3×+3.2×

Profitability

Gross margin86.6%-2.4pp

Operating margin45.3%-1.6pp

Net margin40.6%+0.2pp

FCF margin32.1%-5.6pp

Returns & leverage

Return on equity20.3%+0.3pp

Debt / equity0×—

Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InventoryFirmPurchaseCommitmentLoss.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's tyvaso dpi — loss related to commercial supply agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is United Therapeutics's tyvaso DPI — loss related to commercial supply agreement?: United Therapeutics (UTHR) reported tyvaso DPI — loss related to commercial supply agreement of $26.8M in Q1 2026.
What does tyvaso DPI — loss related to commercial supply agreement mean?: Captures financial losses or charges incurred due to contractual obligations or unfavorable terms within a commercial supply agreement for a specific product. This may include penalties for failing to meet volume commitments or costs associated with securing supply from third-party manufacturers. It highlights operational risks inherent in the product's supply chain strategy.